Member Info for bendis

ps. I actually cashed in some of my NSI funds to buy at <.6... that is now gone.

what did just happen? I thought 0.68 was a typo. that was fast...

@Thordon I'm curious, how do you know that there is one seller and it's from the raise? Is there a pattern you noticed? thanks

Give it a couple of days, it's not a popular stock that reacts instantly :)

Happier morning then.

INRG is reaching fresh new lows, I needed some positive news in my portfolio. That, and stop checking the S&S ISA account. :)

Very low volume today, and only five trades larger than 1 mil (volume).

Tissue Regenix's main market is USA, however they have stated that they are focusing on European expansion as well, targeting UK first, right? Let's look at some background info and relatively recent developments.

* TRX are patent holders for dcell (nb. TRX was co-funded by Uni of Leeds researchers John Fisher CBE and Eileen Ingham see https://www.leeds.ac.uk/spotlight-article/51/at_the_heart_of_regenerative_medicine, also https://www.youtube.com/watch?v=jOcmkTCqXEY and https://www.epo.org/news-events/press/releases/archive/2018/20180424d.html)
* dcell Human Dermis is 1 of (only) 3 skin products that NHS Blood & Transplant offers (based on donors of human tissue). It's the only product out of the three that does not require an HTA license and can be stored at room temperature (the other 2 products require freezing and HTA licensing) https://www.nhsbt.nhs.uk/tissue-and-eye-services/products/skin/
* March 2020: Max and Keira's law passed in England. Implications for organ and tissue donation are big, as there is a considerable wait list for donations. "From 2020, adults in England will be considered potential donors unless they choose to opt out or are excluded." https://www.gov.uk/government/news/opt-out-organ-donation-max-and-keira-s-bill-passed-into-law
* August 2020: TRX partners with a "speciality supplier of orthopaedic and biologic products, for the UK distribution of OrthoPure XT" (this was after obtaining CE mark approval for EU in June 2020). Orthopure is made out of porcine tissue decellularised using dcell techology.
* October 2020: UK manufacturing facility moves to Gartforth (=> savings of £400K annually from 2021)
* December 2020: first Orthopure XT order is shipped
* June 2021: covid-19 restrictions fully lifted in the UK, elective surgeries should pick up considerably, orthopedic surgery tops the list https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00001-1/fulltext

To me, it looks like TRX are positioned to do well in the UK market with their two products (dcell Human Dermis and Orthopure XT), starting 2nd half of 2021. Am I missing anything?

PS. This is not even touching on TRX's US products - biorinse, dermapure, and amnioworks - most of their current revenue is coming from these US products. Or the Germany joint venture GBM-V for cornea products. Silmilar situation in USA, hug e backlog, see https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/cutting-through-the-covid-19-surgical-backlog

sorry not sure what happened to my post, here's the link https://www.youtube.com/watch?v=WSRXnH_LLEs

posted on 23 Feb, apologies if anyone's already posted. Daniel Lee is being interviewed in it.

1,126 views•23 Feb 2021

44

2

SHARE

SAVE

A JOURNEY INTO STOCKS
3.22K subscribers
"In today's video I review a UK penny stock to buy now called Tissue Regenix Group ticker symbol TRX. This penny stock analysis looks at the pro's and cons of investing into this speculative stock."

Damn, I bought SMT and INRG this month, I don't have any money left for TRX top ups... I didn't think it would be going to sub 0.7p anytime soon.

60 mil trade (sell?), whoa.

@ginandmilk: might be because of the pandemic, people's moods are up and down... and there's lots of daydreaming (and more disposable income - to invest - for some, due to no holidaying and low shopping).

We can do a shareholder party in Cyprus if it gets to 3p this summer :)

For that villa to happen I need something like £3 though, I ought to pay the London mortgage first.

Thanks all. I guess the effects of consolidation also depend on when they do it and for what reasons... maybe to gain access to nasdaq would be a good one.

Also I get the feeling that it would be best to consolidate sooner rather than later, say in 1H 2021, before elective surgeries pick up and price (hopefully) skyrockets?!

Newbie question here, sorry if naive: how would the consolidation work, and how would it affect our holdings? I've never owned shares that were consolidated.

As a hypothetical example, if it's 20:1 consolidation and someone has 200,000 shares and price per share when consolidating is 1p, they will be left with 10,000 shares at 20p each? So in theory you don't lose?

I wish I had more money to throw at it but I really ought to keep things diversified even if I am quite optimistic about TRX.

Having said that, if it does dip again to <.7 I might buy 100-200K more shares.

As much as I want TRX to go there, I don't really understand these kinds of posts - what makes you so optimistic that it will actually get to 35p?

3p would be a bit more realistic in the next couple of years, no?

@Ibiza28 we're talking about approx £500K value and Lombard Odier is still the main shareholder even after this. Who knows what they needed the money for... rebalancing their portfolio, other short(er) term opportunities...

@ragingcow38

hasn't the Woodford fund gone bust? How can they still have a 234 mil holding in TRX? Unless I am missing something?

Hi, here's a long list of TRX investors. Some big names there.
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-trx/tissue-regenix-group-shares#ownership

Ownership Name Shares Current Value Change % Portfolio %
15.81%
Lombard Odier Asset Management (Europe) Limited 1,109,400,001 £8.5m -1.55% 0.13%
13.58%
IP Group Plc 953,042,837 £7.3m 0% 6.16%
10.14%
Richard Griffiths 711,250,000 £5.5m 0% no data
10.1%
Premier Fund Managers Limited 709,029,653 £5.4m 0% 0.07%
6.95%
Harwood Capital LLP 487,500,000 £3.7m 119.1% 0.4%
2.82%
Barclays Bank PLC, Wealth and Investment Management Division 197,546,820 £1.5m 0% 0.02%
2.63%
Acacia Research Corporation 184,212,642 £1.4m 0% no data
2.51%
HBOS Investment Fund Managers Limited 176,183,148 £1.4m 0% 0.01%
2.23%
N.F.U. Mutual Unit Managers Limited 156,525,071 £1.2m 0% 0.03%
1.7%
Jupiter Asset Management Limited 119,345,214 £916.6k 0% no data
1.67%
Alan Jonathan Miller 116,886,988 £897.7k 0% no data
1.52%
Jarvis Securities plc, Asset Management Arm 106,871,996 £820.8k 0% 0.05%
1.3%
A J Bell Holdings Limited, Asset Management Arm 91,274,050 £701.0k 0% 0.01%
1.28%
Randeep Grewal 90,000,000 £691.2k 0% no data
1.14%
IG Group Holdings Plc, Asset Management Arm 80,119,659 £615.3k 0% 0.07%
0.8%
Barclays Bank PLC, Securities Investments 56,015,152 £430.2k 0% no data
0.69%
Acamas Strategic Investment Management Ltd 48,331,740 £371.2k 0% no data
0.58%
Jonathan Glenn 40,600,000 £311.8k 0% no data
0.57%
Nomura Holdings Inc, Securities & Investment Arm 40,000,000 £307.2k 0% no data
0.48%
The University of Leeds, Endowment Arm 33,980,127 £261.0k 0% 13.84%
0.47%
Peel Hunt LLP., Asset Management Arm 32,681,058 £251.0k 0% 0.12%
0.45%
Baillie Gifford & Co. 31,235,826 £239.9k 0% no data
0.4%
HSBC Global Asset Management (UK) Limited 28,017,565 £215.2k 0% no data
0.37%
Redmayne Bentley LLP, Asset Management Arm 25,800,000 £198.1k 0% 0.03%
0.36%
Schroder Investment Management Limited 25,550,000 £196.2k 0% no data

... the inventors of dcell and the co-founders of Tissue Regenix in 2006 are Eileen Ingham and John Fisher CBE.

Here you go.
https://www.epo.org/news-events/press/releases/archive/2018/20180424d.html
https://www.epo.org/news-events/events/european-inventor/finalists/2018/ingham.html

https://eps.leeds.ac.uk/mechanical-engineering/staff/59/professor-john-fisher
https://biologicalsciences.leeds.ac.uk/school-biomedical-sciences/staff/88/professor-eileen-ingham-

Cool kids.